Health & Fitness
Health and Fitness
Health and Fitness 
Tue, March 8, 2011
Mon, March 7, 2011
CytRx to Present at the ROTH Capital Partners 23rd Annual OC Growth Stock Conference
LOS ANGELES--([ BUSINESS WIRE ])--CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, announced that President and CEO Steven A. Kriegsman and Vice President of Business Development David Haen, will present at the ROTH Capital Partners (ROTH) 23rd Annual OC Growth Stock Conference on Monday, March 14, 2011, at 10:30 a.m. Pacific time (1:30 p.m. Eastern time). The conference is being held at the Ritz Carlton, Laguna Niguel.
"We believe that CytRx represents a compelling investment opportunity and we are delighted to present at the well-attended ROTH Conference"
aWe believe that CytRx represents a compelling investment opportunity and we are delighted to present at the well-attended ROTH Conference,a said Mr. Kriegsman. aWe will be discussing development of our three oncology compounds, all of which are currently in or are expected soon to be in Phase 2 clinical testing and have the potential to address broad market opportunities in the treatment of various cancers.a
A live webcast of the presentation will be available at [ http://www.cytrx.com ] and a webcast replay will be archived on the Company's website for 90 days.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and development oncology company engaged in the development of high-value human therapeutics. The CytRx oncology pipeline includes three programs in clinical development for cancer indications: bafetinib, tamibarotene and INNO-206. The Company is evaluating bafetinib in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL) and the PROACT Phase 2 clinical trial in advanced prostate cancer, and is conducting a pharmacokinetic clinical trial in brain cancer. With its tumor-targeting pro-drug candidate INNO-206, CytRx plans to initiate Phase 2 proof-of-concept clinical trials as a treatment for pancreatic cancer and soft tissue sarcomas, following an abbreviated safety trial. CytRx's pipeline also includes tamibarotene, which it is testing in patients with non-small-cell lung cancer and which is in a registration clinical trial as a treatment for acute promyelocytic leukemia (APL). For more information on the Company, visit [ http://www.cytrx.com ].